Eburnalritardo

CAS No. 4880-88-0

Eburnalritardo( CH846 | CH-846 | CH 846 | Vinburnine | Eburnal | Eburnamonine )

Catalog No. M14640 CAS No. 4880-88-0

Vinburnine (or eburnamonine, Vincamone) is a vasodilator. Vincamone is a vinca alkaloid and a metabolite of vincamine.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
25MG 37 In Stock
50MG 51 In Stock
100MG 74 In Stock
200MG Get Quote In Stock
500MG Get Quote In Stock
1G Get Quote In Stock

Biological Information

  • Product Name
    Eburnalritardo
  • Note
    Research use only, not for human use.
  • Brief Description
    Vinburnine (or eburnamonine, Vincamone) is a vasodilator. Vincamone is a vinca alkaloid and a metabolite of vincamine.
  • Description
    Vinburnine (or eburnamonine, Vincamone) is a vasodilator. Vincamone is a vinca alkaloid and a metabolite of vincamine.
  • In Vitro
    ——
  • In Vivo
    ——
  • Synonyms
    CH846 | CH-846 | CH 846 | Vinburnine | Eburnal | Eburnamonine
  • Pathway
    Others
  • Target
    Other Targets
  • Recptor
    Others
  • Research Area
    Cardiovascular Disease
  • Indication
    ——

Chemical Information

  • CAS Number
    4880-88-0
  • Formula Weight
    294.39
  • Molecular Formula
    C19H22N2O
  • Purity
    >98% (HPLC)
  • Solubility
    DMSO: 10 mM
  • SMILES
    O=C1N2C3=C(C4=C2C=CC=C4)CCN5C3[C@@](CCC5)(CC)C1
  • Chemical Name
    (13aR)-13a-ethyl-2,3,5,6,13,13a-hexahydro-1H-indolo[3,2,1-de]pyrido[3,2,1-ij][1,5]naphthyridin-12(41H)-one

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1.Riofski MV, et al. J Org Chem. 2011 May 20; 76(10):3676-83.
molnova catalog
related products
  • NT 13

    NT 13 is a partial N-methyl-D-aspartate receptor (NMDAR) agonist used in the study of depression, anxiety, and other related diseases.

  • Amylin (IAPP)(Feline...

    Amylin (IAPP)(Feline)

  • PSB-15160

    PSB-15160 is a compound that inhibits the growth of MCF7 (breast), NCI-H460 (lung) and SF-268 (NCS) cells in the treatment of estrogen-dependent tumours.